Toxicity of cyclosporin A (CsA) against developmental stages of Schistosoma mansoni in mice.
It has been shown elsewhere that the immunosuppressive drug cyclosporin A (CsA) exerts profound schistosomicidal activity when given to infected mice via a multiple administration regime. We show here that a single treatment regime also effects significant reductions in worm burden. Moreover, drug efficacy is maintained at CsA concentrations shown to be subimmunosuppressive in other systems. Subcutaneous treatment effected higher levels of schistosomicidal activity than intraperitoneal or oral treatment, irrespective of whether the drug was given prior to or during infection. Topical application of CsA to the skin site of cercarial penetration, prior to infection resulted in no reduction in worm burden. Systemic release of CsA from a slowly adsorbed, oil-based drug-vehicle combination effected greater levels of killing than when CsA was dissolved in an aqueous drug vehicle. All developmental stages of Schistosoma mansoni were susceptible to killing by a single dose of CsA but, in the case of liver-stage worms, an increased concentration of drug and a longer period between treatment and portal perfusion were needed for killing to be measurable as a reduction in worm numbers.
Munro
G H
GH
Division of Parasitology, National Institute for Medical Research, Mill Hill, London.
McLaren
D J
DJ
D000277:Adjuvants, Pharmaceutic; D000284:Administration, Oral; D000818:Animals; D003524:Cyclosporins / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D012550:Schistosoma mansoni / Q000187:drug effects* / Q000254:growth & development; D012555:Schistosomiasis mansoni / Q000188:drug therapy / Q000469:parasitology*
D000277:Adjuvants, Pharmaceutic; D003524:Cyclosporins